Alisa P. Young
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alisa P. Young has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Diane Medved Harper
University of Michigan
3 shared publications - Ananda Sen
University of Michigan, Ann Arbor, USA
2 shared publications - Dongru Chen
University of Michigan, Ann Arbor, USA
2 shared publications - Heather Walline
Department of Otolaryngology – Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan
2 shared publications - Mack T RuffinIV
University of Michigan
2 shared publications - Marie Claire O'DWyer
Department of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
2 shared publications
Latest Publications
- 14 January 2026
- Published by Elsevier in Preventive Medicine
- Vol. 204, 108512
Major changes in cervical cancer screening in the US
- 14 January 2026
- Published by Elsevier in Preventive Medicine
- Vol. 204, 108512
Major changes in cervical cancer screening in the US
- Open Access
- 30 August 2025
- Published by Elsevier in Preventive Medicine Reports
- Vol. 58, 103222
A United States study of self-collected urine vs clinician-collected cervical sample for HPV and cervical intraepithelial neoplasia grade two or worse detection: Cross-sectional agreement and diagnostic accuracy study
- 30 August 2025
- Published by Elsevier in Preventive Medicine Reports
- Vol. 58, 103222
Open AccessA United States study of self-collected urine vs clinician-collected cervical sample for HPV and cervical intraepithelial neoplasia grade two or worse detection: Cross-sectional agreement and diagnostic accuracy study
- Open Access
- 18 January 2025
- Published by Elsevier in Preventive Medicine Reports
- Vol. 50, 102971
Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping
- 18 January 2025
- Published by Elsevier in Preventive Medicine Reports
- Vol. 50, 102971
Open AccessCervical cancer screening: Impact of collection technique on human papillomavirus detection and genotyping
- 28 August 2016
- Published by Springer Nature
- p. 1157-1166
Diseases of the Pancreas
- 14 February 2015
- Published by Springer Nature
- p. 1-11
Diseases of the Pancreas
- 15 April 2014
- Vol. 89 (8) , 626-32
Diagnosis and management of pancreatic cancer.
Pancreatic cancer remains the fourth leading cause of cancer-related deaths in the United States. Risk factors include family history, smoking, chronic pancreatitis, obesity, diabetes mellitus, heavy alcohol use, and possible dietary factors. Because more than two-thirds of adenocarcinomas occur in the head of the pancreas, abdominal pain, jaundice, pruritus, dark urine, and acholic stools may be presenting symptoms. In symptomatic patients, the serum tumor marker cancer antigen 19-9 can be used to confirm the diagnosis and to predict prognosis and recurrence after resection. Pancreas protocol computed tomography is considered standard for the diagnosis and staging of pancreatic cancer. Although surgical resection is the only potentially curative treatment for pancreatic ductal adenocarcinomas, less than 20% of surgical candidates survive five years. The decision on resectability requires multidisciplinary consultation. Pancreatic resections should be performed at institutions that complete at least 15 of the surgeries annually. Postoperatively, use of gemcitabine or fluorouracil/leucovorin as adjuvant chemotherapy improves overall survival by several months. However, more than 80% of patients present with disease that is not surgically resectable. For patients with locally advanced or metastatic disease, chemoradiotherapy with gemcitabine or irinotecan provides clinical benefit and modest survival improvement. Palliation should address pain control, biliary and gastric outlet obstruction, malnutrition, thromboembolic disease, and depression.
- 15 April 2014
- Vol. 89 (8) , 626-32
Diagnosis and management of pancreatic cancer.
Pancreatic cancer remains the fourth leading cause of cancer-related deaths in the United States. Risk factors include family history, smoking, chronic pancreatitis, obesity, diabetes mellitus, heavy alcohol use, and possible dietary factors. Because more than two-thirds of adenocarcinomas occur in the head of the pancreas, abdominal pain, jaundice, pruritus, dark urine, and acholic stools may be presenting symptoms. In symptomatic patients, the serum tumor marker cancer antigen 19-9 can be used to confirm the diagnosis and to predict prognosis and recurrence after resection. Pancreas protocol computed tomography is considered standard for the diagnosis and staging of pancreatic cancer. Although surgical resection is the only potentially curative treatment for pancreatic ductal adenocarcinomas, less than 20% of surgical candidates survive five years. The decision on resectability requires multidisciplinary consultation. Pancreatic resections should be performed at institutions that complete at least 15 of the surgeries annually. Postoperatively, use of gemcitabine or fluorouracil/leucovorin as adjuvant chemotherapy improves overall survival by several months. However, more than 80% of patients present with disease that is not surgically resectable. For patients with locally advanced or metastatic disease, chemoradiotherapy with gemcitabine or irinotecan provides clinical benefit and modest survival improvement. Palliation should address pain control, biliary and gastric outlet obstruction, malnutrition, thromboembolic disease, and depression.